A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Addpharma

Status and phase: Enrolling; Phase 3

Conditions: Essential Hypertension

Treatments: Drug: AD-227C; Drug: AD-227A; Drug: Placebo of AD-227C; Drug: Placebo of AD-227B; Drug: AD-227B

Study type: Interventional

Funder types: Industry

Identifiers

NCT06441630

AD-227P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Full description

Essential Hypertension

Enrollment: 251 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Patients with Essential Hypertension
• Other inclusions applied

Exclusion criteria

• Patient with Secondary Hypertension
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

251 participants in 3 patient groups

Co-administration of AD-227A and AD-227B

Experimental group

Description:

AD-227A + AD-227B + Placebo of AD-227C

Treatment:

Drug: AD-227B

Drug: Placebo of AD-227C

Drug: AD-227A

AD-227A

Active Comparator group

Description:

AD-227A + Placebo of AD-227B + Placebo of AD-227C

Treatment:

Drug: Placebo of AD-227B

Drug: Placebo of AD-227C

Drug: AD-227A

Co-administration of AD-227A and AD-227C

Active Comparator group

Description:

AD-227A + Placebo of AD-227B + AD-227C

Treatment:

Drug: Placebo of AD-227B

Drug: AD-227C

Drug: AD-227A